| CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma. | CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
de Vos-Hillebrand L, Fietz S, Hillebrand P, Kulcsár Z, Diop MY, Hollick S, Maas AP, Strieth S, Landsberg J, Dietrich D. | 02/21/2024 |
| Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia. | Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia.
Chiesa R, Georgiadis C, Syed F, Zhan H, Etuk A, Gkazi SA, Preece R, Ottaviano G, Braybrook T, Chu J, Kubat A, Adams S, Thomas R, Gilmour K, O'Connor D, Vora A, Qasim W, Base-Edited CAR T Group. | 09/13/2023 |
| Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia. | Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia.
Johansson P, Klein-Hitpass L, Röth A, Möllmann M, Reinhardt HC, Dührsen U, Dürig J. | 09/25/2021 |
| High expression of CD52 in adipocytes: a potential therapeutic target for obesity with type 2 diabetes. | High expression of CD52 in adipocytes: a potential therapeutic target for obesity with type 2 diabetes.
Mao R, Yang F, Zhang Y, Liu H, Guo P, Liu Y, Zhang T., Free PMC Article | 07/31/2021 |
| CD52 Is Elevated on B cells of SLE Patients and Regulates B Cell Function. | CD52 Is Elevated on B cells of SLE Patients and Regulates B Cell Function.
Bhamidipati K, Silberstein JL, Chaichian Y, Baker MC, Lanz TV, Zia A, Rasheed YS, Cochran JR, Robinson WH., Free PMC Article | 07/3/2021 |
| This polyclonal mutational landscape in the PIGA gene was also found in CD52(-) T cells present. | High Mutation Frequency of the PIGA Gene in T Cells Results in Reconstitution of GPI Anchor(-)/CD52(-) T Cells That Can Give Early Immune Protection after Alemtuzumab-Based T Cell-Depleted Allogeneic Stem Cell Transplantation.
Loeff FC, Falkenburg JHF, Hageman L, Huisman W, Veld SAJ, van Egmond HME, van de Meent M, von dem Borne PA, Veelken H, Halkes CJM, Jedema I. | 02/23/2019 |
| soluble CD52 exerts a concerted immunosuppressive effect by first sequestering HMGB1 to nullify its proinflammatory Box B, followed by binding to the inhibitory Siglec-10 receptor, triggering recruitment of SHP1 to the intracellular immunoreceptor tyrosine-based inhibitory motif of Siglec-10 and its interaction with the TCR. | CD52 glycan binds the proinflammatory B box of HMGB1 to engage the Siglec-10 receptor and suppress human T cell function.
Bandala-Sanchez E, G Bediaga N, Goddard-Borger ED, Ngui K, Naselli G, Stone NL, Neale AM, Pearce LA, Wardak A, Czabotar P, Haselhorst T, Maggioni A, Hartley-Tassell LA, Adams TE, Harrison LC., Free PMC Article | 09/22/2018 |
| CD52 is a novel prognostic NSC marker and a potential NSC target in a subset of patients with MDS and AML, which may have clinical implications and may explain clinical effects produced by alemtuzumab in these patients. | Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
Blatt K, Herrmann H, Hoermann G, Willmann M, Cerny-Reiterer S, Sadovnik I, Herndlhofer S, Streubel B, Rabitsch W, Sperr WR, Mayerhofer M, Rülicke T, Valent P. | 02/28/2015 |
| A molecular and computational diagnostic approach identifies FOXP3, ICOS, CD52 and CASP1 as the most informative biomarkers in acute graft-versus-host disease. | A molecular and computational diagnostic approach identifies FOXP3, ICOS, CD52 and CASP1 as the most informative biomarkers in acute graft-versus-host disease.
Cuzzola M, Fiasché M, Iacopino P, Messina G, Martino M, Console G, Fedele R, Massi D, Recchia AG, Irrera G, Morabito F., Free PMC Article | 07/13/2013 |
| carbohydrate moiety of sperm protein interferes with the complement system via binding to C1q | The N-linked carbohydrate moiety of male reproductive tract CD52 (mrt-CD52) interferes with the complement system via binding to C1q.
Hardiyanto L, Hasegawa A, Komori S. | 10/13/2012 |
| CT60 single-nucleotide polymorphism of CTLA4 is a surrogate marker for donor lymphocyte infusion outcome after allogeneic cell transplantation for acute leukemia | CT60 single-nucleotide polymorphism as a surrogate marker for donor lymphocyte infusion outcome after allogeneic cell transplantation for acute leukemia.
Metaxas Y, Bertz H, Spyridonidis A, Spyroupoulou-Vlachou M, Porzelius C, Finke J. | 07/21/2012 |
| Clonal large granular lymphocytes exhibited decreased CD52 expression post-therapy in patients refractory to treatment. | Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia.
Mohan SR, Clemente MJ, Afable M, Cazzolli HN, Bejanyan N, Wlodarski MW, Lichtin AE, Maciejewski JP., Free PMC Article | 08/6/2011 |
| Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) | CD52 gene polymorphism and its potential effect on the response to alemtuzumab in renal transplant recipients.
Oko A, Wyrwicz LS, Glyda M, Idasiak-Piechocka I, Bińczak-Kuleta A, Kaczmarczyk M, Drozd A, Ciechanowicz A, Czekalski S, Oko A, Wyrwicz LS, Glyda M, Idasiak-Piechocka I, Bińczak-Kuleta A, Kaczmarczyk M, Drozd A, Ciechanowicz A, Czekalski S. | 06/30/2010 |
| Our bioinformatics findings suggest that CD52 polymorphism may affect the efficiency of GPI anchor formation and thus may indirectly alter the response to anti-CD52 agents like alemtuzumabin renal transplantation. | CD52 gene polymorphism and its potential effect on the response to alemtuzumab in renal transplant recipients.
Oko A, Wyrwicz LS, Glyda M, Idasiak-Piechocka I, Bińczak-Kuleta A, Kaczmarczyk M, Drozd A, Ciechanowicz A, Czekalski S, Oko A, Wyrwicz LS, Glyda M, Idasiak-Piechocka I, Bińczak-Kuleta A, Kaczmarczyk M, Drozd A, Ciechanowicz A, Czekalski S. | 05/31/2010 |
| We first showed the expression of CD52 in human cumulus cells. CD52 has some functional roles around fertilization in females as well as in males. | CD52 is synthesized in cumulus cells and secreted into the cumulus matrix during ovulation.
Hasegawa A, Takenobu T, Kasumi H, Komori S, Koyama K. | 01/21/2010 |
| The semenogelin-CD52 soluble form is a direct consequence of the liquefaction process in human semen. | The GPI-anchored CD52 antigen of the sperm surface interacts with semenogelin and participates in clot formation and liquefaction of human semen.
Flori F, Ermini L, La Sala GB, Nicoli A, Capone A, Focarelli R, Rosati F, Giovampaola CD. | 01/21/2010 |
| In contrast with CLL, the variable expression of CD52 among other hematologic malignancies suggests that target validation on a case-by-case basis will likely be necessary to guide the rational analysis of CAMPATH therapy. | Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, Shipp MA, Kutok JL. | 01/21/2010 |
| Our data demonstrate differences in the intensity of the CD52 antigen expression between B-lymphocytes and tumor lymphocytes of B-CLL patients, and between B-CLL and SLL tumor cells. CD52 antigen is expressed at low level on CD34(+) cells. | Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases.
Klabusay M, Sukova V, Coupek P, Brychtova Y, Mayer J. | 01/21/2010 |
| The relationship between this differential insertion and differences in glycosylation of rat and human CD52 is discussed. | Different glycoforms of the human GPI-anchored antigen CD52 associate differently with lipid microdomains in leukocytes and sperm membranes.
Ermini L, Secciani F, La Sala GB, Sabatini L, Fineschi D, Hale G, Rosati F. | 01/21/2010 |
| Review article on CD52 structure and function. | CD52 (CAMPATH1).
Hale G. | 01/21/2010 |
| In this study, we identified the antigen of 4C8 mAb as CD52. CD52 is a costimulatory molecule for induction of CD4-positive T cells. | CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.
Watanabe T, Masuyama J, Sohma Y, Inazawa H, Horie K, Kojima K, Uemura Y, Aoki Y, Kaga S, Minota S, Tanaka T, Yamaguchi Y, Kobayashi T, Serizawa I. | 01/21/2010 |
| CD52 is widely expressed on human mast cells (MCs) and Waldenstrom's Macroglobulinemia bone marrow lymphoplasmacytic cells and provide the preclinical rationale for the use of alemtuzumab in the treatment of WM and possibly other MC-related disorders. | CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.
Santos DD, Hatjiharissi E, Tournilhac O, Chemaly MZ, Leleu X, Xu L, Patterson C, Branagan AR, Manning RJ, Ho AW, Hunter ZR, Dimmock EA, Kutok JL, Churchill WH, Castells MC, Tai YT, Anderson KC, Treon SP. | 01/21/2010 |
| HE5(CD52) mRNA and protein, expressed in epithelial cells of the distal epididymis, were not affected by the obstruction of the vas deferens. | Vasectomy influences expression of HE1 but not HE2 and HE5 genes in human epididymis.
Légaré C, Verville N, Sullivan R. | 01/21/2010 |
| A review on CD52 expression and function | CD52 antigen--a review.
Domagała A, Kurpisz M. | 11/3/2006 |